Disease modification in Parkinsonism: obstacles and ways forward.

Area of Science:

• Neuroscience
• Neurology
• Biochemistry

Background:

• Current Parkinson syndrome diagnoses rely on clinical examination, often detecting the disease after significant neuropathological progression.
• Early intervention and neuroprotection are most effective before substantial neurodegeneration occurs.
• Focus is shifting towards identifying early clinical or prodromal stages of Parkinson syndromes.

Purpose of the Study:

• To highlight the need for earlier diagnosis of Parkinson syndromes.
• To discuss the potential of disease subtypes for predicting individual disease trajectories.
• To explore the development of novel fluid and imaging biomarkers for biochemical diagnosis.

Main Methods:

• Review of current diagnostic limitations in Parkinson syndromes.
• Discussion of emerging research in early detection and prodromal Parkinsonism.
• Exploration of developing biomarkers (fluid and imaging) for biochemical diagnosis.
• Analysis of future therapeutic strategies targeting protein aggregation (alpha-synuclein, tau) and neuroinflammation.

Main Results:

• Novel fluid and imaging biomarkers are under development for earlier and more precise biochemical diagnoses.
• Identification of disease subtypes can lead to more accurate predictions of individual disease progression.
• Therapeutic strategies are advancing to target specific neuropathological processes like protein aggregation and spreading.

Conclusions:

• Earlier diagnosis of Parkinson syndromes through biomarkers will enable timely therapeutic interventions.
• Personalized treatment approaches targeting specific proteinopathies and neuroinflammation are expected.
• Drug repurposing offers a viable strategy to accelerate the development of new Parkinson therapies.